[Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)].

This article presents considerations currently under discussion about the probability of HP participation in the ulcer causation as well as information about Rabeprazole efficiency for anti-helicobacter therapy of non-complicated duodenal ulcer (as a result of 7-day anti-helicobacter therapy, the healing of duodenal bulbs was recorded in 82.6% of cases; HP eradication was recorded in 86.9% of cases 4 weeks after the termination of the treatment) based on the analysis of scientific literature data and personal experience. Considerations related to the conduction of a possible study in the field of ulcer therapy that is not associated with Helicobacter pylori are presented.